Dehydration in cancer patients: to treat or not to treat.
نویسندگان
چکیده
Many patients in the terminal phase of their illness experience reduced oral intake before death, due to causes related to their cancer or its treatment. When oral intake is not adequate, dehydration and malnutrition are the obvious results. But these terminally ill patients present a challenge to healthcare providers: to rehydrate these patients or not and, if so, how? Adequate hydration levels are much lower in terminal patients with cancer than in normal adults. Healthcare professionals should assess the patient's hydration needs through personal history, physical examination, and laboratory evaluation before considering the advantages and disadvantages of rehydration, as well as the wishes of the patient and his or her family. In doubtful cases, a short trial of hydration may be appropriate. If hydration is considered, there are a number of methods to consider based on the needs of the patient, including intravenous administration, hypodermoclysis, and proctoclysis. The subcutaneous route is an excellent alternative due to its simplicity, low cost, and feasibility in the home setting.
منابع مشابه
“How should we treat older patients with Metastatic Colorectal Cancer, A Review”
Nearly 50 % of newly diagnosed colorectal cancer, affect people over 70 years of age. Inclusion of older patients in clinical trials has been extremely rare. As a result, there is debate on how to manage these patients because it is still unclear how to balance the therapeutic advantages and toxicities. For patients who do not have comorbid conditions, with performance status (P.S.) 0–1, treatm...
متن کاملFuture of Triple Negative Breast Cancer: Can Immunotherapy Treat This Deadly Subtype of Breast Cancer?
Triple negative breast cancer (TNBC): challenges and solutions via the immune cells TNBC is one of the most complicated types of breast cancer to treat. It is generally diagnosed based on the absence of three receptors: estrogen, progesterone, and human epidermal growth factor receptor 2 (HER2) and is thus defined as a triple negative. TNBC is often more aggressive with lower survival rates...
متن کاملImmunotherapy for Breast Cancer Treatment
Breast cancer, as a heterogeneous disease, includes a wide range of pathological and clinical behaviors. Current treatment protocols, including radiotherapy, chemotherapy, and hormone replacement therapy, are mainly associated with poor response and high rate of recurrence. Therefore, more efforts are needed to develop alternative therapies for this type of cancer. Immunotherapy, as a novel str...
متن کاملInherent radiosensitivity and its impact on breast cancer chemo-radiotherapy
About 10% of apparently normal individuals are sensitive to clastogenic effects of physico-chemical agents. More than 45% of breast cancer patients’ exhibit elevated radiosensitivity. Although the nature of inherent radiosensitivity is not fully understood, but insufficiency and impaired DNA repair mechanism might be prime cause of radiosensitivity. This is evident from genetically affect...
متن کاملInvestigation the potential of Boron neutron capture therapy (BNCT) to treat the lung cancer
Introduction: Boron neutron capture therapy (BNCT) is recommended to treat the glioblastoma tumor. It is well known that neuron beams are more effective treatment than photon beams to treat hypoxia tumors due to interaction of neutron with nucleus and production of heavy particles such as 7Li and alpha particle. In this study to evaluate the suitability of BNCT for treating of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The journal of supportive oncology
دوره 2 6 شماره
صفحات -
تاریخ انتشار 2004